Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Pharma
Regeneron breaks into gMG with FDA nod for siRNA med Livsayis
Now christened Livsayis to treat adults with the most common form of gMG, Regeneron’s medicine wades into a bustling myasthenia gravis market.
Fraiser Kansteiner
Nov 19, 2026 11:16am
AZ beefs up myasthenia gravis pedigree with US, EU Klygefa nods
Nov 16, 2026 10:39am
Argenx reports Q3 sales bump and a new trial requirement
Oct 23, 2026 11:42am
Roche's Enspryng muscles in on Tepezza's TED turf
Oct 16, 2026 9:26am
UCB partners on meal program for MG patients
Apr 21, 2026 6:26am
Argenx's Vyvgart posts ph. 3 win in ocular myasthenia gravis
Feb 26, 2026 11:18am